"Interojo: Expanding Growth Potential... Increasing Valuation Appeal" [Click e-Stock]
On June 10, NH Investment & Securities evaluated Interojo, noting that the company is expected to achieve sales growth and expand its global distribution channels based on its recent FDA 510(k) approval from the U.S. Food and Drug Administration (FDA).
Researcher Sim Eui-seop at NH Investment & Securities stated, "The company recently received FDA 510(k) approval for its own silicone hydrogel (Si-Hy) contact lenses. Following the final approval, Interojo is also pursuing additional approvals for daily disposable and colored lenses, in addition to its monthly clear lenses, and expects to obtain these within the year." He added, "By expanding its certified product lineup, the company is expected to increase its supply volume. Interojo is actively restructuring contracts with overseas partners and broadening its distribution channels in various countries, implementing multifaceted strategies for sales growth."
Interojo has developed and proactively launched silicone hydrogel lenses with maximized oxygen permeability. In addition to clear lenses, the company also offers a lineup of colored lenses designed for cosmetic purposes. Furthermore, Interojo possesses technological competitiveness that enables it to independently design and mass-produce the full spectrum of soft contact lenses, including daily disposable and scheduled replacement lenses.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Researcher Sim emphasized, "With FDA certification and the expansion of global partners, Interojo is projected to achieve record-high results this year. At a price-to-earnings ratio (PER) of 7.3 times, the company's valuation is highly attractive, making it an opportune time to renew interest."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.